title: Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.
abstract: Spleen size ranks among the most important risk factors in chronic myeloid leukemia (CML), but the pathogenic mechanisms of splenic hematopoiesis in CML remain poorly defined. Here, we studied the biology of Bcr-Abl positive leukemia-initiating cells in the spleen, using an inducible transgenic mouse model of CML. Disease kinetics showed greater increases of immature leukemic cells in spleen vs bone marrow (BM). To assess how Bcr-Abl alters the behavior of spleen-derived CML cells, we transplanted these cells either before ('pre-uninduced') or 44 days after ('pre-induced') expression of the oncogene. Mice transplanted with pre-induced spleen cells showed significantly increased neutrophilia and splenomegaly compared with mice receiving pre-uninduced spleen cells, suggesting that Bcr-Abl expression in the donors had increased splenic tumor burden. However, pre-induction also altered the biology of these cells, as shown by a striking increase in erythropoietic potential. These results differ from those of BM-derived CML stem cells where pre-induction of Bcr-Abl had previously been shown to decrease disease transplantability. Moreover, splenic cells were less sensitive to imatinib than BM cells. In conclusion, Bcr-Abl alters the biology of splenic leukemic stem cells by a cell-autonomous mechanism, but the disease phenotype is also influenced by the microenvironment of these cells.
authors.affiliation: Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schemionek
authors.forename: T
authors.initials: T
authors.lastname: Spieker
authors.forename: L
authors.initials: L
authors.lastname: Kerstiens
authors.forename: C
authors.initials: C
authors.lastname: Elling
authors.forename: M
authors.initials: M
authors.lastname: Essers
authors.forename: A
authors.initials: A
authors.lastname: Trumpp
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: C
authors.initials: C
authors.lastname: Müller-Tidow
authors.forename: S
authors.initials: S
authors.lastname: Koschmieder
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000473:pathology*; D004195:Disease Models, Animal; D018450:Disease Progression; D005434:Flow Cytometry; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D013154:Spleen / Q000473:pathology*; D013163:Splenomegaly
chemical_list: D016044:Fusion Proteins, bcr-abl